Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Single-cell Screening Method for the Selection and Recovery of Antibodies with Desired Specificities from Enriched Human Memory B Cell Populations.

Perry ST, Keogh E, Morton M, Koudstaal W, Pascual G.

J Vis Exp. 2019 Aug 22;(150). doi: 10.3791/59809.

PMID:
31498318
2.

Epitope mapping of diverse influenza Hemagglutinin drug candidates using HDX-MS.

Puchades C, Kűkrer B, Diefenbach O, Sneekes-Vriese E, Juraszek J, Koudstaal W, Apetri A.

Sci Rep. 2019 Mar 18;9(1):4735. doi: 10.1038/s41598-019-41179-0.

3.

A small-molecule fusion inhibitor of influenza virus is orally active in mice.

van Dongen MJP, Kadam RU, Juraszek J, Lawson E, Brandenburg B, Schmitz F, Schepens WBG, Stoops B, van Diepen HA, Jongeneelen M, Tang C, Vermond J, van Eijgen-Obregoso Real A, Blokland S, Garg D, Yu W, Goutier W, Lanckacker E, Klap JM, Peeters DCG, Wu J, Buyck C, Jonckers THM, Roymans D, Roevens P, Vogels R, Koudstaal W, Friesen RHE, Raboisson P, Dhanak D, Goudsmit J, Wilson IA.

Science. 2019 Mar 8;363(6431). pii: eaar6221. doi: 10.1126/science.aar6221.

4.

Naturally occurring antibodies isolated from PD patients inhibit synuclein seeding in vitro and recognize Lewy pathology.

Li X, Koudstaal W, Fletcher L, Costa M, van Winsen M, Siregar B, Inganäs H, Kim J, Keogh E, Macedo J, Holland T, Perry S, Bard F, Hoozemans JJ, Goudsmit J, Apetri A, Pascual G.

Acta Neuropathol. 2019 May;137(5):825-836. doi: 10.1007/s00401-019-01974-5. Epub 2019 Feb 25.

5.

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening.

Crespo R, Koudstaal W, Apetri A.

J Vis Exp. 2018 Nov 20;(141). doi: 10.3791/58570.

PMID:
30531722
6.

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia.

De Marco D, Taggenbrock R, Crespo R, Koudstaal W, Ramsburg E, Apetri A.

J Vis Exp. 2018 Nov 9;(141). doi: 10.3791/58576.

PMID:
30474638
7.

Structural Basis for Recognition of a Unique Epitope by a Human Anti-tau Antibody.

Zhang H, Zhu X, Pascual G, Wadia JS, Keogh E, Hoozemans JJ, Siregar B, Inganäs H, Stoop EJM, Goudsmit J, Apetri A, Koudstaal W, Wilson IA.

Structure. 2018 Dec 4;26(12):1626-1634.e4. doi: 10.1016/j.str.2018.08.012. Epub 2018 Oct 11.

PMID:
30318466
8.

Enhancement of therapeutic potential of a naturally occurring human antibody targeting a phosphorylated Ser422 containing epitope on pathological tau.

van Ameijde J, Crespo R, Janson R, Juraszek J, Siregar B, Verveen H, Sprengers I, Nahar T, Hoozemans JJ, Steinbacher S, Willems R, Delbroek L, Borgers M, Dockx K, Van Kolen K, Mercken M, Pascual G, Koudstaal W, Apetri A.

Acta Neuropathol Commun. 2018 Jul 12;6(1):59. doi: 10.1186/s40478-018-0562-9.

9.

A common antigenic motif recognized by naturally occurring human VH5-51/VL4-1 anti-tau antibodies with distinct functionalities.

Apetri A, Crespo R, Juraszek J, Pascual G, Janson R, Zhu X, Zhang H, Keogh E, Holland T, Wadia J, Verveen H, Siregar B, Mrosek M, Taggenbrock R, Ameijde J, Inganäs H, van Winsen M, Koldijk MH, Zuijdgeest D, Borgers M, Dockx K, Stoop EJM, Yu W, Brinkman-van der Linden EC, Ummenthum K, van Kolen K, Mercken M, Steinbacher S, de Marco D, Hoozemans JJ, Wilson IA, Koudstaal W, Goudsmit J.

Acta Neuropathol Commun. 2018 May 31;6(1):43. doi: 10.1186/s40478-018-0543-z.

10.

In Vitro Neutralization Is Not Predictive of Prophylactic Efficacy of Broadly Neutralizing Monoclonal Antibodies CR6261 and CR9114 against Lethal H2 Influenza Virus Challenge in Mice.

Sutton TC, Lamirande EW, Bock KW, Moore IN, Koudstaal W, Rehman M, Weverling GJ, Goudsmit J, Subbarao K.

J Virol. 2017 Nov 30;91(24). pii: e01603-17. doi: 10.1128/JVI.01603-17. Print 2017 Dec 15.

11.

Immunological memory to hyperphosphorylated tau in asymptomatic individuals.

Pascual G, Wadia JS, Zhu X, Keogh E, Kükrer B, van Ameijde J, Inganäs H, Siregar B, Perdok G, Diefenbach O, Nahar T, Sprengers I, Koldijk MH, der Linden EC, Peferoen LA, Zhang H, Yu W, Li X, Wagner M, Moreno V, Kim J, Costa M, West K, Fulton Z, Chammas L, Luckashenak N, Fletcher L, Holland T, Arnold C, Anthony Williamson R, Hoozemans JJ, Apetri A, Bard F, Wilson IA, Koudstaal W, Goudsmit J.

Acta Neuropathol. 2017 May;133(5):767-783. doi: 10.1007/s00401-017-1705-y. Epub 2017 Mar 24.

12.

HA Antibody-Mediated FcγRIIIa Activity Is Both Dependent on FcR Engagement and Interactions between HA and Sialic Acids.

Cox F, Kwaks T, Brandenburg B, Koldijk MH, Klaren V, Smal B, Korse HJ, Geelen E, Tettero L, Zuijdgeest D, Stoop EJ, Saeland E, Vogels R, Friesen RH, Koudstaal W, Goudsmit J.

Front Immunol. 2016 Sep 29;7:399. eCollection 2016.

13.

Matrix-M™ adjuvation broadens protection induced by seasonal trivalent virosomal influenza vaccine.

Cox F, Saeland E, Baart M, Koldijk M, Tolboom J, Dekking L, Koudstaal W, Lövgren Bengtsson K, Goudsmit J, Radošević K.

Virol J. 2015 Dec 8;12:210. doi: 10.1186/s12985-015-0435-9.

14.

A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen.

Impagliazzo A, Milder F, Kuipers H, Wagner MV, Zhu X, Hoffman RM, van Meersbergen R, Huizingh J, Wanningen P, Verspuij J, de Man M, Ding Z, Apetri A, Kükrer B, Sneekes-Vriese E, Tomkiewicz D, Laursen NS, Lee PS, Zakrzewska A, Dekking L, Tolboom J, Tettero L, van Meerten S, Yu W, Koudstaal W, Goudsmit J, Ward AB, Meijberg W, Wilson IA, Radošević K.

Science. 2015 Sep 18;349(6254):1301-6. doi: 10.1126/science.aac7263. Epub 2015 Aug 24.

15.

Protection against H5N1 by multiple immunizations with seasonal influenza vaccine in mice is correlated with H5 cross-reactive antibodies.

Roos A, Roozendaal R, Theeuwsen J, Riahi S, Vaneman J, Tolboom J, Dekking L, Koudstaal W, Goudsmit J, Radošević K.

Vaccine. 2015 Mar 30;33(14):1739-47. doi: 10.1016/j.vaccine.2015.01.070. Epub 2015 Feb 7.

PMID:
25659276
16.

Transient humoral protection against H5N1 challenge after seasonal influenza vaccination of humans.

Roozendaal R, Tolboom J, Roos A, Riahi S, Theeuwsen J, Bujny MV, Klaren V, Korse HJ, Dekking L, Grootenhuis A, Weverling GJ, Koudstaal W, Goudsmit J, Radošević K.

PLoS One. 2014 Jul 30;9(7):e103550. doi: 10.1371/journal.pone.0103550. eCollection 2014.

17.

Mechanisms of hemagglutinin targeted influenza virus neutralization.

Brandenburg B, Koudstaal W, Goudsmit J, Klaren V, Tang C, Bujny MV, Korse HJ, Kwaks T, Otterstrom JJ, Juraszek J, van Oijen AM, Vogels R, Friesen RH.

PLoS One. 2013 Dec 11;8(12):e80034. doi: 10.1371/journal.pone.0080034. eCollection 2013.

18.

A common solution to group 2 influenza virus neutralization.

Friesen RH, Lee PS, Stoop EJ, Hoffman RM, Ekiert DC, Bhabha G, Yu W, Juraszek J, Koudstaal W, Jongeneelen M, Korse HJ, Ophorst C, Brinkman-van der Linden EC, Throsby M, Kwakkenbos MJ, Bakker AQ, Beaumont T, Spits H, Kwaks T, Vogels R, Ward AB, Goudsmit J, Wilson IA.

Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):445-50. doi: 10.1073/pnas.1319058110. Epub 2013 Dec 11.

19.

Highly conserved protective epitopes on influenza B viruses.

Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R, Ekiert DC, Lee JH, Metlagel Z, Bujny MV, Jongeneelen M, van der Vlugt R, Lamrani M, Korse HJ, Geelen E, Sahin Ö, Sieuwerts M, Brakenhoff JP, Vogels R, Li OT, Poon LL, Peiris M, Koudstaal W, Ward AB, Wilson IA, Goudsmit J, Friesen RH.

Science. 2012 Sep 14;337(6100):1343-8. doi: 10.1126/science.1222908. Epub 2012 Aug 9.

20.

A highly conserved neutralizing epitope on group 2 influenza A viruses.

Ekiert DC, Friesen RH, Bhabha G, Kwaks T, Jongeneelen M, Yu W, Ophorst C, Cox F, Korse HJ, Brandenburg B, Vogels R, Brakenhoff JP, Kompier R, Koldijk MH, Cornelissen LA, Poon LL, Peiris M, Koudstaal W, Wilson IA, Goudsmit J.

Science. 2011 Aug 12;333(6044):843-50. doi: 10.1126/science.1204839. Epub 2011 Jul 7.

21.

Rapid generation of a well-matched vaccine seed from a modern influenza A virus primary isolate without recourse to eggs.

Hartgroves LC, Koudstaal W, McLeod C, Moncorgé O, Thompson CI, Ellis J, Bull C, Havenga MJ, Goudsmit J, Barclay WS.

Vaccine. 2010 Apr 9;28(17):2973-9. doi: 10.1016/j.vaccine.2010.02.012. Epub 2010 Feb 25.

PMID:
20188682
22.

New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets.

Friesen RH, Koudstaal W, Koldijk MH, Weverling GJ, Brakenhoff JP, Lenting PJ, Stittelaar KJ, Osterhaus AD, Kompier R, Goudsmit J.

PLoS One. 2010 Feb 8;5(2):e9106. doi: 10.1371/journal.pone.0009106.

23.

Pre- and postexposure use of human monoclonal antibody against H5N1 and H1N1 influenza virus in mice: viable alternative to oseltamivir.

Koudstaal W, Koldijk MH, Brakenhoff JP, Cornelissen LA, Weverling GJ, Friesen RH, Goudsmit J.

J Infect Dis. 2009 Dec 15;200(12):1870-3. doi: 10.1086/648378.

PMID:
19911992
24.

Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics.

Koudstaal W, Hartgroves L, Havenga M, Legastelois I, Ophorst C, Sieuwerts M, Zuijdgeest D, Vogels R, Custers J, de Boer-Luijtze E, de Leeuw O, Cornelissen L, Goudsmit J, Barclay W.

Vaccine. 2009 Apr 28;27(19):2588-93. doi: 10.1016/j.vaccine.2009.02.033. Epub 2009 Feb 20.

PMID:
19428865
25.

Safety and efficacy in geese of a PER.C6-based inactivated West Nile virus vaccine.

Samina I, Havenga M, Koudstaal W, Khinich Y, Koldijk M, Malkinson M, Simanov M, Perl S, Gijsbers L, Weverling GJ, Uytdehaag F, Goudsmit J.

Vaccine. 2007 Nov 28;25(49):8338-45. Epub 2007 Oct 15.

PMID:
17977629
26.

Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector.

Kostense S, Koudstaal W, Sprangers M, Weverling GJ, Penders G, Helmus N, Vogels R, Bakker M, Berkhout B, Havenga M, Goudsmit J.

AIDS. 2004 May 21;18(8):1213-6.

PMID:
15166541
27.

Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.

Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, Havenga MJ, Truitt DM, Sumida SM, Kishko MG, Arthur JC, Korioth-Schmitz B, Newberg MH, Gorgone DA, Lifton MA, Panicali DL, Nabel GJ, Letvin NL, Goudsmit J.

J Immunol. 2004 May 15;172(10):6290-7.

28.

Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors.

Sumida SM, Truitt DM, Kishko MG, Arthur JC, Jackson SS, Gorgone DA, Lifton MA, Koudstaal W, Pau MG, Kostense S, Havenga MJ, Goudsmit J, Letvin NL, Barouch DH.

J Virol. 2004 Mar;78(6):2666-73.

29.

Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors.

Sprangers MC, Lakhai W, Koudstaal W, Verhoeven M, Koel BF, Vogels R, Goudsmit J, Havenga MJ, Kostense S.

J Clin Microbiol. 2003 Nov;41(11):5046-52.

30.

Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity.

Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Béthune MP, Kostense S, Penders G, Helmus N, Koudstaal W, Cecchini M, Wetterwald A, Sprangers M, Lemckert A, Ophorst O, Koel B, van Meerendonk M, Quax P, Panitti L, Grimbergen J, Bout A, Goudsmit J, Havenga M.

J Virol. 2003 Aug;77(15):8263-71.

Supplemental Content

Loading ...
Support Center